ES3075688T3 - Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative - Google Patents
Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivativeInfo
- Publication number
- ES3075688T3 ES3075688T3 ES18860379T ES18860379T ES3075688T3 ES 3075688 T3 ES3075688 T3 ES 3075688T3 ES 18860379 T ES18860379 T ES 18860379T ES 18860379 T ES18860379 T ES 18860379T ES 3075688 T3 ES3075688 T3 ES 3075688T3
- Authority
- ES
- Spain
- Prior art keywords
- glp
- glucagon
- peptide
- derivative
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170126577 | 2017-09-28 | ||
| PCT/KR2018/011586 WO2019066586A1 (ko) | 2017-09-28 | 2018-09-28 | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3075688T3 true ES3075688T3 (en) | 2026-08-06 |
Family
ID=65902619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18860379T Active ES3075688T3 (en) | 2017-09-28 | 2018-09-28 | Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative |
Country Status (22)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111312UA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| EP4082561A4 (en) * | 2019-12-24 | 2024-02-07 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof |
| US20230110689A1 (en) | 2020-03-30 | 2023-04-13 | Zealand Pharma A/S | Agonist combination |
| CN115697375A (zh) * | 2020-04-03 | 2023-02-03 | 韩美药品株式会社 | 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物 |
| IL298298A (en) | 2020-05-22 | 2023-01-01 | Hanmi Pharm Ind Co Ltd | A liquid formulation of a long-acting conjugate of glp–2 |
| CA3182260A1 (en) | 2020-06-09 | 2021-12-16 | Gleb Feldman | Manufacture, formulation and dosing of apraglutide |
| CA3201916A1 (en) * | 2020-12-24 | 2022-06-30 | Hanmi Pharm. Co., Ltd. | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
| US20250276044A1 (en) * | 2022-04-18 | 2025-09-04 | Hanmi Pharm. Co., Ltd. | COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE |
| JP2026501948A (ja) | 2022-12-23 | 2026-01-19 | ハンミ ファーマシューティカル カンパニー リミテッド | Glp-2誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DK1360202T3 (da) * | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
| US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| ES2347902T3 (es) * | 2004-04-23 | 2010-11-22 | Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 | Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina. |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| KR101746686B1 (ko) * | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체 |
| ES2687651T3 (es) * | 2011-09-12 | 2018-10-26 | Amunix Operating Inc. | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos |
| KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
-
2018
- 2018-09-28 AR ARP180102806A patent/AR113258A1/es unknown
- 2018-09-28 AU AU2018339210A patent/AU2018339210B2/en active Active
- 2018-09-28 MX MX2020004453A patent/MX2020004453A/es unknown
- 2018-09-28 KR KR1020180116327A patent/KR102681143B1/ko active Active
- 2018-09-28 BR BR112020006189-1A patent/BR112020006189A2/pt unknown
- 2018-09-28 IL IL273528A patent/IL273528B2/en unknown
- 2018-09-28 TW TW110126453A patent/TWI794897B/zh active
- 2018-09-28 FI FIEP18860379.9T patent/FI3689898T3/fi active
- 2018-09-28 ES ES18860379T patent/ES3075688T3/es active Active
- 2018-09-28 JP JP2020517828A patent/JP7751381B2/ja active Active
- 2018-09-28 EA EA202090571A patent/EA202090571A1/ru unknown
- 2018-09-28 WO PCT/KR2018/011586 patent/WO2019066586A1/ko not_active Ceased
- 2018-09-28 CA CA3084326A patent/CA3084326A1/en active Pending
- 2018-09-28 DK DK18860379.9T patent/DK3689898T3/da active
- 2018-09-28 CN CN201880074180.4A patent/CN111433221B/zh active Active
- 2018-09-28 SG SG11202002563WA patent/SG11202002563WA/en unknown
- 2018-09-28 PT PT188603799T patent/PT3689898T/pt unknown
- 2018-09-28 TW TW107134398A patent/TWI795443B/zh active
- 2018-09-28 EP EP18860379.9A patent/EP3689898B1/en active Active
-
2020
- 2020-03-19 PH PH12020550105A patent/PH12020550105A1/en unknown
- 2020-03-24 ZA ZA2020/01888A patent/ZA202001888B/en unknown
- 2020-03-27 US US16/832,634 patent/US11530249B2/en active Active
- 2020-03-28 SA SA520411644A patent/SA520411644B1/ar unknown
-
2022
- 2022-04-14 US US17/721,048 patent/US12703730B2/en active Active
- 2022-11-02 US US17/979,531 patent/US20230090790A1/en not_active Abandoned
-
2023
- 2023-07-06 JP JP2023111438A patent/JP2023138505A/ja active Pending
-
2024
- 2024-01-22 KR KR1020240009740A patent/KR102681144B1/ko active Active